Colinz Labs, a company in the Pharmaceuticals industry, reported revenue of ₹1.55 crore and net profit of ₹0.13 crore for the September 2026 quarter.
Colinz Labs (BSE: COLINZ) closed at ₹64.25 on 20 Nov 2026, up 49.2% over the past year. Its market capitalisation is ₹16 crore and it trades at 33.0 times earnings.
Incorporated in 1986, Colinz Laboratories is in the business of manufacturing and trading in pharmaceutical formulations
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.